We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Barchart on MSN2d
Biogen Stock Outlook: Is Wall Street Bullish or Bearish?Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and ...
Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback